Eupraxia Pharmaceuticals EPRX
$5.80 −$0.32 (-5.23%)
Market closed · Nov 20, 8:10 pm ET · Last extended-hours $5.80 0.00%
Open$6.11
Prev close$6.12
Day range$5.69 – $6.42
Volume361.7K
Market cap$390.16M
P/E (TTM)–
Dividend yield–
Fundamentals
Latest reported quarter: Q3, ended Sep 2026
Revenue$0.00
Operating profit-$16.16M-134.8% YoY
Net profit-$15.25M-139.4% YoY
Diluted EPS-$0.23-21.1% YoY
Free cash flow-$11.46M-151.0% YoY
Operating cash flow-$11.33M
Revenue, last 8 quarters
Net profit, last 8 quarters
Diluted EPS by quarter
Free cash flow by quarter
Annual revenue
Profitability & balance sheet
Return on equity-78.9%
Return on assets-52.1%
Return on invested capital-80.4%
Current ratio12.25
Liabilities / assets10.0%
Cash & investments$126.42M
Total debt$2.91M
Net cash (debt)$123.51M
Income statement
| Line item | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 ANNUAL | 2025 Q4 |
|---|---|---|---|---|---|
| Total Operating Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Expense | $16.16M | $18.10M | $15.96M | $38.43M | $16.16M |
| Selling and Admin Expenses | $5.34M | $5.30M | $4.78M | $17.10M | $8.30M |
| -General & Admin Expense | $5.34M | $5.30M | $4.78M | $17.10M | $8.30M |
| Research & Development | $10.82M | $12.81M | $11.17M | $21.33M | $7.87M |
| Operating Profit | -$16.16M | -$18.10M | -$15.96M | -$38.43M | -$16.16M |
| Net Non-Operating Interest Income (Expense) | $1.22M | $1.39M | $1.07M | $1.41M | $666,921.00 |
| Non-Operating Interest Income | $1.22M | $1.39M | $1.07M | $1.41M | $666,921.00 |
| Other Income (Expense) | -$313,763.00 | $2.25M | $2.24M | -$1.57M | -$1.21M |
| Gain on Sale of Security | -$312,356.00 | $2.25M | $2.24M | -$1.56M | -$1.21M |
| Special Income (Charges) | -$1,407.00 | -$2,704.00 | $0.00 | -$2,562.00 | -$1,487.00 |
| -Gain on Sale of Property/Plant/Equipment | -$1,407.00 | -$2,704.00 | $0.00 | -$2,562.00 | -$1,487.00 |
| Pretax Profit | -$15.26M | -$14.46M | -$12.64M | -$38.59M | -$16.71M |
| Tax | -$7,170.00 | $30,381.00 | $13,905.00 | $19,091.00 | $11,339.00 |
| Net Profit | -$15.25M | -$14.49M | -$12.65M | -$38.61M | -$16.72M |
| Profit from Continuing Operations | -$15.25M | -$14.49M | -$12.65M | -$38.61M | -$16.72M |
| Minority Interests | -$6,189.00 | -$6,478.00 | -$1,415.00 | -$29,509.00 | -$10,084.00 |
| Net Income to Parent Company | -$15.24M | -$14.49M | -$12.65M | -$38.58M | -$16.71M |
| Net Income to Common Stockholders | -$15.24M | -$15.08M | -$12.65M | -$38.58M | -$16.71M |
| Basic EPS | -$0.23 | -$0.23 | -$0.23 | -$1.03 | -$0.37 |
| Diluted EPS | -$0.23 | -$0.23 | -$0.23 | -$1.03 | -$0.37 |
| Preferred Stock Dividends | – | $596,050.00 | – | – | – |
| Non-Operating Interest Expense | – | – | – | $0.00 | $0.00 |
Balance sheet
| Line item | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 ANNUAL | 2025 Q4 |
|---|---|---|---|---|---|
| Total Assets | $134.56M | $139.91M | $145.35M | $86.15M | $86.15M |
| Total Current Assets | $129.95M | $136.80M | $142.13M | $85.10M | $85.10M |
| Cash and Cash Equivalents & Short-Term Investments | $126.42M | $133.66M | $138.88M | $80.56M | $80.56M |
| -Cash and Cash Equivalents | $75.18M | $52.43M | $58.50M | $80.56M | $80.56M |
| -Short Term Investments | $51.25M | $81.23M | $80.38M | – | – |
| Receivables | $202,171.00 | $688,219.00 | $663,235.00 | $674,226.00 | $674,226.00 |
| -Taxes Receivable | $202,171.00 | $688,219.00 | $663,235.00 | $674,226.00 | $674,226.00 |
| Prepaid Assets | $3.33M | $2.46M | $2.58M | $3.86M | $3.86M |
| Total Non-Current Assets | $4.61M | $3.10M | $3.23M | $1.05M | $1.05M |
| Net PPE | $4.56M | $3.05M | $3.17M | $987,126.00 | $987,126.00 |
| -Gross PPE | $5.39M | $3.81M | $3.86M | $1.63M | $1.63M |
| -Accumulated Depreciation | -$830,243.00 | -$756,638.00 | -$693,467.00 | -$644,167.00 | -$644,167.00 |
| Non-Current Prepaid Assets | $50,594.00 | $53,702.00 | $61,754.00 | $64,332.00 | $64,332.00 |
| Total Liabilities | $13.52M | $10.23M | $9.17M | $5.70M | $5.70M |
| Total Current Liabilities | $10.61M | $8.55M | $7.36M | $5.63M | $5.63M |
| Payables | $1.16M | $1.10M | $468,451.00 | $1.52M | $1.52M |
| -Total Tax Payable | $14,460.00 | $21,184.00 | $23,390.00 | $1,606.00 | $1,606.00 |
| -Other Payable | $1.14M | $1.08M | $445,061.00 | $1.52M | $1.52M |
| Current Accrued Expenses | $8.94M | $7.29M | $6.69M | $4.03M | $4.03M |
| Short-Term Debt and Capital Lease Obligation | $511,977.00 | $159,877.00 | $203,510.00 | $78,452.00 | $78,452.00 |
| -Current Capital Lease Obligation | $511,977.00 | $159,877.00 | $203,510.00 | $78,452.00 | $78,452.00 |
| Total Non-Current Liabilities | $2.91M | $1.68M | $1.80M | $75,910.00 | $75,910.00 |
| Long Term Debt and Capital Lease Obligation | $2.91M | $1.68M | $1.80M | $75,910.00 | $75,910.00 |
| -Long Term Capital Lease Obligation | $2.91M | $1.68M | $1.80M | $75,910.00 | $75,910.00 |
| Total Equity | $121.05M | $129.67M | $136.19M | $80.45M | $80.45M |
| Stockholders' Equity | $121.05M | $131.28M | $137.78M | $82.04M | $82.04M |
| Capital Stock | $305.57M | $293.70M | $285.24M | $225.15M | $225.15M |
| -Common Stock | $276.05M | $264.18M | $255.50M | $195.41M | $195.41M |
| -Preferred Stock | $29.52M | $29.52M | $29.74M | $29.74M | $29.74M |
| Additional Paid-In Capital | $34.15M | $41.31M | $39.27M | $28.52M | $28.52M |
| Retained Earnings | -$211.96M | -$196.72M | -$182.23M | -$169.58M | -$169.58M |
| Gains/Losses Not Affecting Retained Earnings | -$6.71M | -$7.01M | -$4.48M | -$2.04M | -$2.04M |
| Minority Interests | $0.00 | -$1.60M | -$1.60M | -$1.60M | -$1.60M |
Cash flow
| Line item | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 ANNUAL | 2025 Q4 |
|---|---|---|---|---|---|
| Operating Cash Flow | -$11.33M | -$13.09M | -$10.15M | -$28.55M | -$9.73M |
| Net cash flow from continuing operations | -$11.33M | -$13.09M | -$10.15M | -$28.55M | -$9.73M |
| Net Income from Continuing Operations | -$15.25M | -$14.49M | -$12.65M | -$38.61M | -$16.72M |
| Gain/Loss from Continuing Operations | $288,139.00 | -$2.24M | -$2.23M | $1.57M | $1.19M |
| Depreciation & Depletion & Amortization | $183,656.00 | $134,935.00 | $90,146.00 | $237,717.00 | $72,806.00 |
| Other Non-Cash Items | -$83,095.00 | -$907,891.00 | -$408,712.00 | -$76,945.00 | -$18,589.00 |
| Change in Working Capital | $1.40M | $1.38M | $2.80M | -$713,700.00 | -$231,592.00 |
| -Change in Receivables | $501,554.00 | -$26,168.00 | $23,964.00 | -$431,449.00 | -$528,267.00 |
| -Change in Prepaid Assets | -$874,190.00 | $49,457.00 | $1.24M | -$2.64M | -$1.47M |
| -Change in Payables and Accrued Expense | $1.77M | $1.35M | $1.54M | $2.36M | $1.76M |
| Net cash flow from investing | $29.94M | -$173,092.00 | -$80.05M | -$588,947.00 | -$193,301.00 |
| Net Cash Flow from Continuing Investing Activities | $29.94M | -$173,092.00 | -$80.05M | -$588,947.00 | -$193,301.00 |
| Net PPE Purchase and Sale | -$133,957.00 | -$173,092.00 | -$326,953.00 | -$588,947.00 | -$193,301.00 |
| Net Investment Purchase and Sale | $30.07M | $0.00 | -$79.72M | – | – |
| Financing Cash Flow | $4.18M | $7.48M | $68.58M | $76.06M | $1.49M |
| Net Cash Flow from Continuing Financing Activities | $4.18M | $7.48M | $68.58M | $76.06M | $1.49M |
| Net Common Stock Issuance | $0.00 | -$9.27M | $58.63M | $73.89M | $0.00 |
| Proceeds from Stock Option Exercised | $4.18M | $16.75M | $9.95M | $2.17M | $1.49M |
| Ending Cash Balance | $75.18M | $52.43M | $58.50M | $80.56M | $80.56M |
| Net Change in Cash | $22.79M | -$5.79M | -$21.62M | $46.92M | -$8.43M |
| Beginning Cash Balance | $52.43M | $58.50M | $80.56M | $33.10M | $88.96M |
| Effect of Exchange Rate Changes | -$42,560.00 | -$283,988.00 | -$448,176.00 | $544,813.00 | $33,894.00 |
| Free Cash Flow | -$11.46M | -$13.27M | -$10.47M | -$29.14M | -$9.92M |
| Net Issuance Payments Of Debt | – | – | – | $0.00 | $0.00 |
No comments yet — be the first to weigh in on EPRX.
Sign in to join the discussion.